By Fineline Cube 
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) has unveiled its 2025 interim results, showcasing a remarkable 74.3% year-on-year revenue jump to RMB 730 million for the first half of the year. This significant growth is predominantly fueled by the escalating sales volume of its cornerstone drug, orelabrutinib, and a licensing agreement upfront payment from Prolium.
Revenue Breakdown
Drug revenue alone experienced a robust 53.5% year-on-year growth, reaching RMB 640 million in H1 2025. This uptick is largely attributed to orelabrutinib’s performance following its inclusion in China’s National Reimbursement Drug List (NRDL), especially for its exclusive marginal zone lymphoma indication. The company’s commercialization team has also played a pivotal role in driving this growth.
Profitability and Efficiency
InnoCare Pharma’s net loss for the first half of 2025 contracted by 86.7% year-on-year to RMB 36 million. This substantial reduction is a testament to the company’s increased operating revenue and enhanced cost efficiency initiatives.
R&D and Innovation
The company has ramped up its R&D expenditure by 6.9% year-on-year to RMB 450 million in H1 2025. This investment is geared towards establishing a differentiated R&D platform and propelling more Phase III clinical projects forward.
Global Strategic Moves
InnoCare Pharma has further expanded its global footprint through strategic collaborations. In January 2025, the company entered into partnerships with Conon Biotherapeutics and Prolium Bioscience to license the development and commercialization of the CD20×CD3 bispecific antibody ICP-B02 (CM355) to Prolium, marking a significant step in its global product development and commercialization strategy.-Fineline Info & Tech